Report of Foreign Issuer (6-k)
April 13 2020 - 8:33AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: April 2020
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On
April 13, 2020, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”),
issued a press release with respect to the selection of the Company by the Israel Innovation Authority to receive a $1.5 million
grant to fund the Company’s planned COVID-19 and sepsis clinical programs. A copy of such press release is furnished as
Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Enlivex
Therapeutics Ltd.
|
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/
Shai Novik
|
|
|
Name:
Title:
|
Shai
Novik
Executive Chairman
|
Date:
April 13, 2020
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024
